UNSPSC 51283917: Sulfamerazine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR1SAB295F, chemically known as sulfanilamide, n(sup 1)-(4-methyl-2-pyrimidinyl)- but generally known as sulfamerazine, which bears US NIH Compound Identifier 5325. European Medicines Agency schedules Sulfamerazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10708MIG.

UNSPSC 51283917 Sulfamerazine, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The code's abstract definition — a sulfonamide antibiotic — does not match the two recent opportunities posted under it. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (neither sulfamerazine), totaling $2,999,999.11 over 12 months with two renewal options. Seminole County, Florida issued an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, which are opioid antagonists and harm-reduction equipment, not sulfonamides. Both opportunities suggest state and local health agencies are using this code to tag broad pharmaceutical and medical-supply procurement, but neither opportunity actually solicits sulfamerazine itself.

Activity under the code concentrates in Illinois and Florida, with Illinois Department of Public Health and Seminole County as recent issuers. The Illinois contract, awarded in August 2026, used an Invitation for Bid process under a cooperative purchasing vehicle; the Seminole County opportunity, posted in June 2026 with a July 26, 2023 due date (likely a data error in the source), specified quarterly deliveries and included potential FEMA funding and federal compliance requirements. The mismatch between the code's nominal scope and the actual pharmaceutical products being solicited suggests either miscoding by the issuing bodies or use of the code as a catch-all for pharmaceutical warehouse and supply-chain work. Firms pursuing opportunities under this code should verify the actual commodity or service required before bid preparation, as the code designation may not reflect what is genuinely being purchased.